Global Health Limited Earnings Summary — Q4 FY2026
Medanta Reports Record Quarterly Revenue of ₹1,159 Cr Amid Capacity Expansion
Key Takeaways
- Revenue reached an all-time high of ₹1,159 crore in Q4 FY2026, marking a 24.5% year-on-year increase.
- Net profit recovered significantly to ₹142 crore from ₹95 crore in the preceding quarter (Q3 FY26), showing strong sequential resilience.
- Operating margins (OPM) stabilized at 21%, up from 19% in Q3 but remaining below the 24% seen in the same quarter last year.
- The company is undergoing an aggressive capex phase, with ₹977 crore spent in FY26, primarily targeting Noida and Lucknow expansions.
- Borrowings increased to ₹1,190 crore to fund greenfield and brownfield expansion, impacting interest costs which rose to ₹27 crore.
- While top-line growth remains robust, depreciation and interest costs are rising in tandem with the scaling of new units.
- Medanta maintains a high-complexity clinical focus, which supports high Average Revenue Per Occupied Bed (ARPOB).
Management Guidance
Management remains focused on a 'cluster-based' dominance strategy, prioritizing expansion in North and East India while integrating digital health and home care into the ecosystem.
Sentiment Shift
Improving
Outlook
The outlook remains strong for volume growth as new beds in Lucknow Phase II and Noida come online, though profitability may face short-term moderation due to heavy depreciation and staffing for new facilities.
← Back to Global Health Limited AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from Global Health Limited's latest annual report and public disclosures. It is for informational purposes only and is not investment advice.